Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

August 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • FEATURED
  • COVID UPDATE: COVID elixir by Oxford is unsafe? Trials put on hold yet again!

Calcium channels prohibit pathogen entry

Molecules for Life- Thioredoxin System

COVID UPDATE: COVID elixir by Oxford is unsafe? Trials put on hold yet again!
  • BiotechToday
  • FEATURED
  • Latest
  • World

COVID UPDATE: COVID elixir by Oxford is unsafe? Trials put on hold yet again!

bioxone September 9, 2020September 9, 2020

-Binayak Das, Team bioXone

The highly-awaited trials for the Covid-19 vaccine formulation by Oxford have yet again been put on hold for a second time this year. The reason behind this has to do with certain safety concerns, as informed to Stat News, on Tuesday. This measure was taken by AstraZeneca Plc. right after they observed potentially hazardous reaction-response, in a trial participant. A statement coming directly from AstraZeneca Plc personnel stated that their standard review process instigated a pause to vaccination, so as to allow the review of their safety data. 
The details about what the safety issue is exactly have not yet been made public by neither AstraZeneca nor by the researchers at the University of Oxford, although they mentioned that the patient is not in critical condition and will supposedly, recover soon, according to Stat News.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged CORONA VACCINE Covid Oxford VACCINE VACCINE IN INDIA

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • DNA-Tales
  • FEATURED
  • Latest
  • Scientists' Corner

Molecules for Life- Thioredoxin System

bioxone September 9, 2020

–Esha Sircar & Dr. Rajib Sengupta, Amity Institute of Biotechnology, Amity University Kolkata The thioredoxin (Trx) system is a major antioxidant system that maintains the intracellular redox state. It contains Trx, a redox-active protein, which regulates the activity of various enzymes including those that function to counteract oxidative stress within the cell. Trx, NADPH, and […]

Related Post

  • BiotechToday
  • FEATURED
  • Latest
  • World

Personalization of the Immune System to fight Cancer

bioxone September 8, 2020September 8, 2020

-Prama Ghosh, Amity University Kolkata Cancer Immunotherapy uses the immune system to eradicate cancer cells and prevent their spread in the body. It needs to be personalized because anticancer immune responses can be inhibited in various ways varying from person to person.  There are pharmaceutical and non – pharmaceutical approaches cancer immunotherapy which includes monoclonal […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Catalase: Antioxidant Treatment for COVID-19

bioxone October 2, 2020October 1, 2020

-Thota Kanishka Rao, Amity University Kolkata Researchers have discovered that a drug, Catalase, might be the solution to the ongoing coronavirus pandemic. Catalase is a naturally occurring enzyme having the potential as a therapeutic drug treat COVID-19 symptom and suppress the replication of the virus inside the body. Catalase is produced naturally and employed by […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Single-Use Rapid PCR Testing for STDs

bioxone December 5, 2020December 5, 2020

Thota Kanishka Rao, Amity University Kolkata Convenient recognition and treatment are significant for the control of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. The target of this study carried out by researchers was to gauge the presentation of the Visby Medical Sexual Health Test, a solitary use, point-of-care PCR gadget. Point-of-care testing refers to the […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy